Compass Therapeutics, Inc. made a public disclosure
SEC 8-KRead source ↗
Compass Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 0 selling4 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds147 adding, 89 cuttingOf 52 active managers that changed their stake, 32 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Share count rising (dilution): Diluted shares outstanding rose 31.8% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Compass Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 31.8% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 95% and a beta of 1.3 against the S&P 500.
- Heavily shorted. 27.8% of the shares available to trade are sold short (6.1 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results: FY2025 Q4
- Earnings per share
- -$0.13 against an average estimate of -$0.11: missed by 20.0%
- Share reaction
- +13.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
- Next report
- November 5, 2026; average EPS estimate -$0.13
Price chart
- 1 day-2.4%
- 1 week+2.8%
- 1 month-10.4%
- This year-85.7%
- 1 year-79.5%
- 5 years-78.4%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.40
Growth
- Share count change
- +31.8%
Earnings
- Last results
- August 6, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Results
Compass Therapeutics, Inc. reported results
SEC 8-KRead source ↗
No model value for Compass Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Compass Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.1 ~$0.1–$0.4 | Left out: out of range vs price (0.14x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Compass Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 5, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.13 (range −$0.15 to −$0.10) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.48 | −15% | — | 0% |
| Next | −$0.54 | −11% | $7m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +11.6% on 90 days ago. In the last 30 days, 3 analysts raised Compass Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.43 | −$0.46 |
| 60 days ago | −$0.49 | −$0.54 |
| 30 days ago | −$0.48 | −$0.54 |
| 7 days ago | −$0.48 | −$0.54 |
| Now | −$0.48 | −$0.54 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.11 | −$0.13 | −20.0% |
| Mar 2026 | −$0.10 | −$0.10 | 0.0% |
| Dec 2025 | −$0.09 | −$0.09 | −2.6% |
| Sept 2025 | −$0.13 | −$0.08 | +39.6% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 27.8% of tradable shares
- Days to cover
- 6.08 at average volume
- Short interest, 1 month
- +0% to October 15, 2026
- Held by institutions
- 88% of shares
- Held by insiders
- 12.5% of shares
- Employees
- 39 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| CMPX | +59% | −69% | −7% | +270% | −86% |
| Industry peers (median) | −57% | −17% | −29% | −5% | −26% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| CMPX | 58% | 8% | 42% | 67% | 27% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| CMPX | −64% | −75% | −65% | −63% | −89% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since April 5, 2021: 92% from April 16, 2021 to October 26, 2026. Getting back needed a 1078% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.75 – $6.69
- From 52-week high
- −88.5%
- vs 50-day average
- −46.3%
- vs 200-day average
- −75.7%
- Volatility (1 year)
- 95%
- Beta vs S&P 500
- 1.34
Share price after results
- Next day
- 8 up, 4 down typical move ±8.7%
- After a week
- 7 up, 5 down typical move ±17.9%
- After a month
- 8 up, 4 down typical move ±39.6%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | +13.8% | +0.5% | +19.6% | +25.9% |
| May 5, 2026 | −3.6% | +2.2% | −3.6% | +9.8% |
| March 5, 2026 | −3.2% | −1.9% | −8.8% | −3.5% |
| January 6, 2026 | +9.2% | +0.3% | +11.8% | +24.6% |
| November 5, 2025 | +5.5% | −0.7% | +29.3% | +45.9% |
| August 11, 2025 | +17.4% | +0.9% | +6.3% | +30.4% |
| May 8, 2025 | +3.4% | +0.6% | +14.8% | +46.0% |
| February 27, 2025 | −2.4% | −0.1% | −11.8% | −33.0% |
| January 8, 2025 | +23.8% | −1.4% | +74.8% | +172.7% |
| November 12, 2024 | −11.1% | −0.3% | −25.3% | −20.5% |
| August 12, 2024 | +10.1% | +1.7% | +9.2% | +37.6% |
| May 13, 2024 | +0.9% | +0.5% | 0.0% | −25.0% |
Fundamentals
Financial statements
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 0 | 1 | 0 |
| EBITDA | −50 | −56 | −73 |
| Operating income | −50 | −57 | −73 |
| Net income | −42 | −49 | −66 |
| Growth (year on year) | |||
| Revenue | — | — | −100.0% |
| Margins | |||
| EBITDA margin | — | <−999% | — |
| Operating margin | — | <−999% | — |
| Net margin | — | <−999% | — |
| Free-cash-flow margin | — | <−999% | — |
| Cash flow | |||
| Cash from operations | −41 | −45 | −49 |
| Capital spending | 0 | 0 | 0 |
| Free cash flow | −41 | −45 | −49 |
| Stock-based pay | 6 | 9 | 8 |
| Free cash flow after stock pay | −47 | −53 | −58 |
| Balance sheet | |||
| Cash | 24 | 43 | 31 |
| Total debt | 0 | 0 | 0 |
| Net debt (negative = net cash) | −24 | −43 | −31 |
| Diluted shares | 127m | 137m | 158m |
| Quarter | 2023 Q3 Sept 2023 | 2023 Q4 Dec 2023 | 2024 Q2 Jun 2024 | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | −12 | −15 | −15 | −12 | −16 | −21 | −16 | −18 |
| Operating income | −12 | −15 | −15 | −12 | −17 | −21 | −16 | −18 |
| Net income | −10 | −13 | −13 | −10 | −15 | −20 | −14 | −16 |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | — | — | −100.0% | — | — |
| Margins | ||||||||
| EBITDA margin | — | — | <−999% | — | — | — | — | — |
| Operating margin | — | — | <−999% | — | — | — | — | — |
| Net margin | — | — | <−999% | — | — | — | — | — |
| Free-cash-flow margin | — | — | <−999% | — | — | — | — | — |
| Cash flow | ||||||||
| Cash from operations | −6 | −12 | −11 | −11 | −9 | −12 | −11 | −13 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −6 | −12 | −11 | −11 | −9 | −12 | −11 | −13 |
| Stock-based pay | 2 | 2 | 2 | 2 | 2 | 3 | 1 | 2 |
| Free cash flow after stock pay | −8 | −14 | −13 | −13 | −11 | −15 | −12 | −15 |
Dividends, buybacks and capital spending
- Diluted share count
- +31.8%
- year over year
Who owns it
Funds buying and selling- Reported value
- $363M
- Institutions reporting
- 216
- Shares held vs prior quarter
- ▼ 4.3%
- Positions opened / closed
- 63 / 45
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Tang Capital Management LLC | $39.4M | 18.0M | 10.8% | ▲ 7.1% |
| Orbimed Advisors LLC | $33.3M | 15.2M | 9.2% | 0.0% |
| Montanova Capital, LLC | $30.9M | 14.1M | 8.5% | ▼ 1.4% |
| Blackrock, Inc. | $24.7M | 11.3M | 6.8% | ▲ 18.7% |
| State Street Corp | $21.8M | 10.0M | 6.0% | ▲ 48.7% |
| Enavate Sciences Gp, LLC | $17.1M | 7.8M | 4.7% | 0.0% |
| Vivo Capital, LLC | $17M | 7.8M | 4.7% | ▼ 18.7% |
| Vanguard Capital Management LLC | $13.4M | 6.1M | 3.7% | ▲ 1.4% |
| Palo Alto Investors LP | $12.8M | 5.8M | 3.5% | ▲ 285.1% |
| Millennium Management LLC | $10.3M | 4.7M | 2.8% | ▲ 457.0% |
| Geode Capital Management, LLC | $8.4M | 3.8M | 2.3% | ▲ 7.0% |
| Vanguard Portfolio Management LLC | $8.3M | 3.8M | 2.3% | ▲ 248.3% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Compass Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $96,850 4 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $96,850 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Lerner Neil Chief Accounting Officer | October 1, 2026 | Buy | 20,000 | $0.92 | $18,400 |
| Lerner Neil Chief Accounting Officer | September 24, 2026 | Buy | 2,500 | $1.14 | $2,850 |
| Anderman Jonathan General Counsel | April 29, 2026 | Buy | 25,000 | $1.89 | $47,250 |
| Lerner Neil Chief Accounting Officer | April 29, 2026 | Buy | 15,000 | $1.89 | $28,350 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 6, 2026
- May 5, 2026
- March 5, 2026
- January 6, 2026
- November 5, 2025
- August 11, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Compass Therapeutics, Inc. in brief
- What does Compass Therapeutics, Inc. do?
- Compass Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Compass Therapeutics, Inc.'s stock ticker?
- Compass Therapeutics, Inc. trades under the ticker CMPX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Compass Therapeutics, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Tang Capital Management LLC, Orbimed Advisors LLC and Montanova Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- What is Compass Therapeutics, Inc.'s market cap?
- On December 31, 2025, Compass Therapeutics, Inc.'s market capitalisation was about $847M and net debt of -$30.6M. Market figures come from third-party market data and may be delayed.
- Are insiders buying or selling Compass Therapeutics, Inc. stock?
- Over the last 12 months, Compass Therapeutics, Inc.'s directors and officers reported 4 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Compass Therapeutics, Inc.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Compass Therapeutics, Inc. announces its own schedule.
Follow research on Compass Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.